PMID

Data

Article Title

Organization

Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum.

Schering-Plough Research Institute

Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.

Uppsala University

Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.

Schering-Plough Research Institute

Control of hepatitis C: a medicinal chemistry perspective.

University Of Wollongong

Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.

Peking University

SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease.

Merck Research Laboratories

Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.

Uppsala University

NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.

Boehringer Ingelheim Pharmaceuticals

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

Boehringer Ingelheim Pharmaceuticals

Peptide-based inhibitors of the hepatitis C virus serine protease.

Boehringer Ingelheim (Canada)

P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.

Schering-Plough Research Institute

Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.

Wyeth Research

Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.

Wyeth Research

Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.

Schering-Plough Research Institute

Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.

Schering-Plough Research Institute

Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.

Pharmaceutical Research Institute

The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.

Mrl Rome

P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.

Eli Lilly

P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.

Eli Lilly

Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.

Schering-Plough Research Institute

Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.

Vertex Pharmaceuticals

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.

Vertex Pharmaceuticals

Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.

University Of Massachusetts Medical School

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.

Boehringer Ingelheim (Canada)

Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease.

Schering-Plough Research Institute

Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.

Vertex Pharmaceuticals

Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures.

Mrl Rome

Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.

Bristol-Myers Squibb

Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors.

Bristol-Myers Squibb Pharmaceutical Research Institute

Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.

Mrl Rome

Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.

Glaxosmithkline

Capped dipeptide alpha-ketoacid inhibitors of the HCV NS3 protease.

Irbm, Mrl Rome

P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.

Bristol-Myers Squibb Pharmaceutical Research Institute

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease.

Celera

Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.

Schering-Plough Research Institute

Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.

Irbm, Mrl Rome

A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.

Irbm, Mrl Rome

Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase.

Roche Discovery Welwyn

Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.

Bristol-Myers Squibb Pharmaceutical Research Institute

The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase.

Roche Discover Welwyn

Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.

Institute Of Molecular And Cell Biology

Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors.

Dupont Pharmaceuticals

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

Boehringer Ingelheim (Canada)

Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.

Merck Research Laboratories

A review on HCV inhibitors: Significance of non-structural polyproteins.

Institute Of Pharmaceutical Education And Research

P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.

Bristol-Myers Squibb Research And Development

Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants.

University Of Massachusetts Medical School

Pan-NS3 protease inhibitors of hepatitis C virus based on an R

Uppsala University

The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.

Bristol-Myers Squibb

Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.

Bristol-Myers Squibb